Ibrutinib Now Approved for Children With Chronic GVHD

Ibrutinib is now approved for chronic graft-vs-host disease in children aged 1 to 12 years and is available in a new oral suspension formulation.
FDA Approvals

source https://www.medscape.com/viewarticle/979729?src=rss